7 completed. 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 7 |
Follow Chronic Renal Failure: new trials by email Literature Review of Chronic Renal Failure trials Research Report on Chronic Renal Failure
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study to Compare the Pharmacokinetics and Safety of D113 With CKD-349 in Healthy Volunteers CKD-349 F1 Tab., CKD-349 F2 Tab., D113 Tab. - Chronic Renal Failure | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 25 | 2021-07-19 | 2024-01-24 |
| Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Polycystic Kidney Disease Intravenous injection autologous mesenchymal stem cells - Chronic Renal Failure, Polycystic Kidney Disease | Phase 1 | Completed | Royan Institute | 6 | 2014-03-01 | 2016-01-05 |
| A Study Comparing the Effects of Epoetin Hospira and Epogen/Epoetin Alfa (Amgen) When Administered IV in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment Epoetin Hospira, Epogen - Chronic Renal Failure | Phase 1 | Completed | Hospira, now a wholly owned subsidiary of Pfizer | 107 | 2010-07-01 | 2017-03-20 |
| Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects CTAP101 Capsules, CTAP101 Injection - Chronic Kidney Disease, Secondary Hyperparathyroidism | Phase 1 | Completed | OPKO IP Holdings II, Inc. | 28 | 2009-05-01 | 2014-09-30 |
| Safety Study of TRK-820 for Patient With Hemodialysis nalfurafine hydrochloride - Chronic Renal Failure | Phase 1 | Completed | SK Chemicals Co., Ltd. | 16 | 2008-12-01 | 2010-11-25 |
| Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT) CTAP201 Injection, Doxercalciferol - Chronic Kidney Disease, Secondary Hyperparathyroidism | Phase 1 | Completed | OPKO IP Holdings II, Inc. | 24 | 2008-11-01 | 2014-09-29 |
| Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers Placebo, peginesatide - Anemia, Chronic Kidney Disease | Phase 1 | Completed | Affymax | 28 | 2004-08-01 | 2012-12-21 |
Kidney Failure, Chronic (7) · Renal Insufficiency, Chronic (3) · Hyperparathyroidism (2) · Hyperparathyroidism, Secondary (2) · Kidney Diseases (2) · Parathyroid Diseases (2) · Renal Insufficiency (2) · Anemia (1) · Neoplasms (1) · Polycystic Kidney Diseases (1)
Chronic Disease (7) · Disease Attributes (7) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Male Urogenital Diseases (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Urogenital Diseases (7) · Urologic Diseases (7) · Kidney Diseases (5) · Renal Insufficiency (5) · Renal Insufficiency, Chronic (4) · Endocrine System Diseases (2) · Abnormalities, Multiple (1) · Ciliopathies (1)
1 alpha-hydroxyergocalciferol (1) · Epoetin Alfa (1) · TRK 820 (1) · hematide (1) · peginesatide (1)
OPKO IP Holdings II, Inc. (2) · Affymax (1) · Chong Kun Dang Pharmaceutical (1) · Hospira, now a wholly owned subsidiary of Pfizer (1) · Royan Institute (1) · SK Chemicals Co., Ltd. (1)
United States (3) · South Korea (2) · Iran (1) · United Kingdom (1)
Joel Melnick, MD (2) · Atieh Makhlough, MD (1) · Hamid Gourabi, PhD (1) · Jang Hee Hong (1) · Nasser Aghdami, MD,PhD (1) · Reza Moghadasali, PhD (1) · Wooseong Huh, MD, PhD (1)
2004 (1)